Acta Scientific Pharmacology

Research Article Volume 2 Issue 9

Post-Covid Lungs Fibrosis: An Worrying Experience of Covid19 Survivors!!

SM AA Mamun1*, Zafor Iqbal2, Sanaullah Sarker3, QT Islam4, Arif Mahmud5 and Sania Ahsan6

1Senior Consultant of Respiratory Medicine, Evercare Hospitals, Dhaka, Bangladesh
2Consultant, Intensive Care Unit, Evercare Hospitals, Dhaka, Bangladesh
3Senior Specialist of Respiratory Medicine, Evercare Hospitals, Dhaka, Bangladesh
4Professor of Medicine, Popular Medical College, Dhaka, Bangladesh
5Public Health Specialist and Deputy Director of Evercare Hospitals, Dhaka, Bangladesh
6Senior Consultant of Radiology and Imaging, Evercare Hospitals, Dhaka, Bangladesh

*Corresponding Author: SM AA Mamun, Senior Consultant of Respiratory Medicine, Evercare Hospitals, Dhaka, Bangladesh.

Received: July 27, 2021; Published: August 16, 2021

Abstract

Introduction: Patients recovering from confirmed COVID-19, particularly moderate to severe disease, those who needing HDU/ICU support with HFNC and MV, experienced different symptoms ranging from tiredness, fatigue to severe exertional dyspnea. HRCT of Chest of these patients showing persistent radiological abnormalities simulating progressive fibrotic lung disease. Lung function including DLCO revealed moderate to severe reduction of CO transfer factor. In case of patients recovered from moderate to severe COVID-19 pneumonia, lung injury and fibrosis is a big problem and it is one of the most worrying long-term complications. We observed that lung fibrosis was documented in previous SARS and MERS pathology, and current observational studies suggests that pulmonary fibrosis could also complicate infection by SARS-CoV-2.

Objective: The objective of our study is to early segregation of patients who have potential to develop such serious complication, thus giving a chance for early detection of post-COVID-19 lung fibrosis and to prevent or at least modify such disabling complication by proper and early intervention.

Results: From April 2020 to June 2021, 110 patients at Evercare hospitals Dhaka Bangladesh, who had admitted in HDU and ICU with florid clinical manifestations and confirmed COVID-19 by RT-PCR, were evaluated by follow-up HRCT of chest and symptoms scoring. Different radiological signs and residual fibrotic changes in follow up HRCT was considered. CT severity score (CT-SS) is a good predictor for disease progression, that leads to pulmonary fibrosis.. In our study we have taken mild to moderate group (CT-SS of 1-17) and severe group (CT-SS of 18-25).

There are no documented predisposing factors that may directly influence the development of post-COVID-19 lung fibrosis, some predicting factors such as old age, multiple comorbidity, long term cigarette smoking and prolong HFNC or mechanical ventilation may be the inciting factors.

Conclusion: Early detection of potential cases of post-COVID-19 lungs fibrosis may give us the opportunity to prevent or at least modify such disabling condition.

Keywords: COVID-19; Fibrosis; Antifibrotic

References

  1. Franceschi C., et al. “Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity”. Frontiers in Immunology 8 (2017): 982.
  2. Levin AT., et al. “Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications”. European Journal of Epidemiology12 (2020): 1123-1138.
  3. Welch C. Geriatric Medicine Research C. “Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study”. Age Ageing (2021).
  4. Kalchiem-Dekel O., et al. “Interstitial lung disease and pulmonary fibrosis: A practical approach for general medicine physicians with focus on the medical history”. Journal of Clinical Medicine 7 (2018): 476.
  5. Lechowicz K., et al. “COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection”. Journal of Clinical Medicine 9 (2020): 1917.
  6. Ueno M., et al. “Hypoxia-inducible factor-1α mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis”. American Journal of Physiology - Lung Cellular and Molecular Physiology 300 (2011): L740-L752.
  7. Sgalla G., et al. “Idiopathic pulmonary fibrosis: pathogenesis and management”. Respiratory Research1 (2018): 32.
  8. Pardo A and Selman M. “The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis”. American Journal of Respiratory Cell and Molecular Biology 2 (2021): 163-172.
  9. Abramson MJ., et al. “Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study”. Thorax 10 (2020): 864-869.
  10. Molyneaux PL and Maher TM. “The role of infection in the pathogenesis of idiopathic pulmonary fibrosis”. European Respiratory Society 129 (2013): 376-381.
  11. Burnham EL., et al. “Detection of fibroproliferation by chest high-resolution CT scan in resolving ARDS”. Chest5 (2014): 1196-1204.
  12. Hui DS., et al. “Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors”. Thorax 5 (2005): 401-409.
  13. Das KM., et al. “Follow-up chest radiographic findings in patients with MERS-CoV after recovery”. Indian Journal of Radiology and Imaging 3 (2017): 342-349.
  14. Xing ZH., et al. “Thin-section computed tomography detects long-term pulmonary sequelae 3 years after novel influenza A virus-associated pneumonia”. Chinese Medical Journal (Engl) 7 (2015): 902-908.
  15. Qiao J., et al. “Pulmonary fibrosis induced by H5N1 viral infection in mice”. Respiratory Research 10 (2009): 107.
  16. Naik PK and Moore BB. “Viral infection and aging as cofactors for the development of pulmonary fibrosis”. Expert Review of Respiratory Medicine 6 (2010): 759-771.
  17. Carsana L., et al. “Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-center descriptive study”. Lancet Infectious Disease (2020): 1473-3099 (20): 30434-30435.
  18. Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan China”. JAMA Internal Medicine7 (2020): 934-943.
  19. Wong K., et al. “Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period”. Journal of Computer Assisted Tomography 6 (2002): 790-795.
  20. Sansone A., et al. “Addressing male sexual and reproductive health in the wake of COVID-19 outbreak”. Journal of Endocrinological Investigation2 (2021): 223-231.
  21. Lee EY and Singh R. “Follow-up chest radiographic findings in patients with MERS-CoV after recovery”. Indian Journal of Radiology and Imaging 3 (2021): 342-349.
  22. Vardavas CI., et al. “COVID-19 and smoking: a systematic review of the evidence”. Tobacco Induced Diseases 18 (2020): 20.
  23. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 10229 (2020): 1054-1062.
  24. Franceschi C., et al. “Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity”. Frontiers in Immunology 8 (2017): 982.

Citation

Citation: SM AA Mamun., et al. “Post-Covid Lungs Fibrosis: An Worrying Experience of Covid19 Survivors!!".Acta Scientific Pharmacology 2.9 (2021): 02-08.

Copyright

Copyright: © 2020 SM AA Mamun., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US